ASX:BD1

Stock Analysis Report

BARD1 Life Sciences

Executive Summary

BARD1 Life Sciences Limited focuses on developing and commercializing non-invasive diagnostic tests for early detection of cancer in Australia.

Snowflake

Fundamentals

Flawless balance sheet with weak fundamentals.

Risks

  • BARD1 Life Sciences has significant price volatility in the past 3 months.
  • BARD1 Life Sciences is not covered by any analysts.

Share Price & News

How has BARD1 Life Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

20.0%

ASX:BD1

0.3%

AU Healthcare

-0.03%

AU Market


1 Year Return

93.5%

ASX:BD1

9.5%

AU Healthcare

5.6%

AU Market

BD1 outperformed the Healthcare industry which returned 9.5% over the past year.

BD1 outperformed the Market in Australia which returned 5.6% over the past year.


Share holder returns

BD1IndustryMarket
7 Day20.0%0.3%-0.03%
30 Day20.0%0.7%1.7%
90 Day66.7%9.4%6.2%
1 Year99.5%93.5%13.3%9.5%11.8%5.6%
3 Year47.2%42.9%5.0%-4.6%38.1%20.1%
5 Yearn/a54.2%32.7%43.5%12.1%

Price Volatility Vs. Market

How volatile is BARD1 Life Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BARD1 Life Sciences undervalued based on future cash flows and its price relative to the stock market?

8.88x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for BARD1 Life Sciences to establish if it is available at moderate discount.

Unable to calculate intrinsic value for BARD1 Life Sciences to establish if it is available at substantial discount.


Price Based on Earnings

BARD1 Life Sciences is loss making, we can't compare its value to the AU Healthcare industry average.

BARD1 Life Sciences is loss making, we can't compare the value of its earnings to the Australia market.


Price Based on Expected Growth

Unable to calculate PEG ratio for BARD1 Life Sciences, we can't assess if its growth is good value.


Price Based on Value of Assets

BARD1 Life Sciences is overvalued based on assets compared to the AU Healthcare industry average.


Next Steps

Future Growth

How is BARD1 Life Sciences expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BARD1 Life Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has BARD1 Life Sciences performed over the past 5 years?

-18.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

BARD1 Life Sciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare BARD1 Life Sciences's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare BARD1 Life Sciences's 1-year growth to the AU Healthcare industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if BARD1 Life Sciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if BARD1 Life Sciences has efficiently used its assets last year compared to the AU Healthcare industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if BARD1 Life Sciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is BARD1 Life Sciences's financial position?


Financial Position Analysis

BARD1 Life Sciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

BARD1 Life Sciences's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

BARD1 Life Sciences has no debt.

BARD1 Life Sciences had no debt 5 years ago.


Balance Sheet

Low level of unsold assets.

BARD1 Life Sciences has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

BARD1 Life Sciences has sufficient cash runway for 2 years based on current free cash flow.

BARD1 Life Sciences has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 41.7% each year.


Next Steps

Dividend

What is BARD1 Life Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate BARD1 Life Sciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate BARD1 Life Sciences's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as BARD1 Life Sciences has not reported any payouts.

Unable to verify if BARD1 Life Sciences's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as BARD1 Life Sciences has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of BARD1 Life Sciences's salary, the management and board of directors tenure and is there insider trading?

2.0yrs

Average board tenure


CEO

Leearne Hinch

2.7yrs

Tenure

AU$403,147

Compensation

Dr. Leearne Maree Hinch, BSc., B.V.M.S., M.R.C.V.S., M.B.A. has been the Chief Executive Officer of BARD1 Life Sciences Limited since November 7, 2016. Dr. Hinch is a biotechnology executive and consultant ...


CEO Compensation Analysis

Leearne's remuneration is about average for companies of similar size in Australia.

Leearne's compensation has increased whilst company is loss making.


Board Age and Tenure

2.0yrs

Average Tenure

The average tenure for the BARD1 Life Sciences board of directors is less than 3 years, this suggests a new board.


Insider Trading

More shares have been bought than sold by BARD1 Life Sciences individual insiders in the past 3 months.


Recent Insider Transactions

BuyAU$99,99615 Jul 19
Philip Powell
EntityIndividual
Role
Member of the Board of Directors
Shares5,000,000
Max PriceAU$0.02
BuyAU$99,99615 Jul 19
Robert Johnston
EntityIndividual
Role
Member of the Board of Directors
Shares5,000,000
Max PriceAU$0.02
BuyAU$2,386,12119 Jun 19
Merchant Funds Management Pty Ltd
EntityCompany
Shares119,349,963
Max PriceAU$0.022
SellAU$474,97019 Jun 19
Merchant Funds Management Pty Ltd
EntityCompany
Shares23,909,752
Max PriceAU$0.02
BuyAU$1,849,95719 Jun 19
Jeffrey Emmanuel
EntityIndividual
Shares92,500,000
Max PriceAU$0.02
BuyAU$1,369,96819 Jun 19
David Williams
EntityIndividual
Shares68,500,000
Max PriceAU$0.02
SellAU$204,97902 Dec 18
Irmgard Irminger-Finger
EntityIndividual
Role
Founder
Member of the Board of Directors
Shares8,599,683
Max PriceAU$0.024
SellAU$664,36331 Oct 18
Credit Suisse, Investment Banking and Securities Investments
EntityCompany
Shares16,222,101
Max PriceAU$0.058
BuyAU$279,40931 Oct 18
Credit Suisse, Investment Banking and Securities Investments
EntityCompany
Shares5,105,070
Max PriceAU$0.057
BuyAU$263,58529 Oct 18
Credit Suisse, Investment Banking and Securities Investments
EntityCompany
Shares9,390,584
Max PriceAU$0.031
BuyAU$33,53124 Oct 18
Credit Suisse, Investment Banking and Securities Investments
EntityCompany
Shares2,579,447
Max PriceAU$0.013
SellAU$371,73010 Sep 18
Credit Suisse, Investment Banking and Securities Investments
EntityCompany
Shares21,736,381
Max PriceAU$0.017
BuyAU$9,77810 Sep 18
Credit Suisse, Investment Banking and Securities Investments
EntityCompany
Shares19,636,381
Max PriceAU$0.0005

Ownership Breakdown


Management Team

  • Peter Gunzburg (67yo)

    Executive Chairman & MD

    • Compensation: A$63.88k
  • Leearne Hinch

    Chief Executive Officer

    • Tenure: 2.7yrs
    • Compensation: A$403.15k
  • Pauline Collinson

    Company Secretary

    • Tenure: 17.7yrs
    • Compensation: A$129.08k
  • Irmgard Irminger-Finger

    Founder

    • Compensation: A$150.00k

Board Members

  • Peter Gunzburg (67yo)

    Executive Chairman & MD

    • Tenure: 17.8yrs
    • Compensation: A$63.88k
  • Philip Powell (62yo)

    Director

    • Tenure: 0.1yrs
  • Max Johnston

    Director

    • Tenure: 0.1yrs
  • Irmgard Irminger-Finger

    Founder

    • Tenure: 8.8yrs
    • Compensation: A$150.00k
  • Samuel Janes

    Member of Advisory Board

    • Tenure: 2.0yrs

Company Information

BARD1 Life Sciences Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BARD1 Life Sciences Limited
  • Ticker: BD1
  • Exchange: ASX
  • Founded:
  • Industry: health care services
  • Sector: healthcare
  • Market Cap: AU$38.281m
  • Shares outstanding: 1.37b
  • Website: Click here

Location

  • BARD1 Life Sciences Limited
  • Harry Perkins Institute of Medical Research
  • L2/QQ Block
  • Nedlands
  • Western Australia
  • 6009
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BD1ASX (Australian Securities Exchange)YesOrdinary SharesAUAUDJun 2016
EGQDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJun 2016
BD1CHIA (Chi-X Australia)YesOrdinary SharesAUAUDJun 2016

Biography

BARD1 Life Sciences Limited focuses on developing and commercializing non-invasive diagnostic tests for early detection of cancer in Australia. It is developing BARD1 lung cancer test, a non-invasive blood ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/07/17 10:39
End of Day Share Price2019/07/17 00:00
Earnings2018/12/31
Annual Earnings2018/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.